1. Home
  2. LXEO

as 06-20-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Nasdaq

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

Founded: 2017 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 93.9M IPO Year: 2023
Target Price: $16.60 AVG Volume (30 days): 697.6K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.31 EPS Growth: N/A
52 Week Low/High: $1.45 - $19.50 Next Earning Date: 08-11-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

LXEO Daily Stock ML Predictions

Stock Insider Trading Activity of Lexeo Therapeutics Inc. (LXEO)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Robertson Jenny LXEO Chief Legal Officer May 16 '25 Sell $2.77 521 $1,445.25 63,098
Townsend Richard Nolan LXEO Chief Executive Officer May 16 '25 Sell $2.77 1,074 $2,979.28 221,173
See Tai Sandi LXEO Chief Development Officer May 16 '25 Sell $2.77 367 $1,018.06 59,242

Share on Social Networks: